摘要
目的探讨奥沙利铂联合替吉奥对比XELOX(奥沙利铂联合卡培他滨)方案在胃癌术后辅助化疗中的临床疗效。方法将81例胃癌术后患者分为治疗组和对照组,治疗组(n=41)给予奥沙利铂联合替吉奥方案化疗,对照组(n=40)给予XEOLX方案化疗。结果治疗组与对照组的1年和2年无复发生存期(RFS)分别为51.3%和61.5%,25.6%和20.5%,两组比较差异无统计学意义(P=0.361,P=0.591)。治疗组和对照组1年和2年总生存期分别为64.1%和69.2%,30.8%和25.6%,两组比较差异无统计学意义(P=0.631,P=0.615)。两组的不良反应主要表现为骨髓抑制、胃肠道反应、手足综合征、口腔黏膜炎、末梢神经毒性及肝、肾功能损伤。对照组手足综合征的发生率明显高于治疗组,差异有统计学意义(P=0.001),所有不良反应经对症治疗后均好转。结论奥沙利铂联合替吉奥与奥沙利铂联合卡培他滨在胃癌术后治疗中疗效相当,不良反应患者可耐受。
Objective To investigate the efficacy of oxaliplatin plus S-1 versus the XELOX（oxatiplatm ＋ capemtablne） program in the adjuvant chemotherapy in the patients with postoperative gastric cancer. Methods A total of 81 cases with postoperative gas- tric cancer were randomly divided into the treatment group and the control group. The treatment group （41 cases） received the chemotherapy of oxaliplatin ＋S-1,while control group was given the chemotherapy of XEOLX program. Results The 1-year and 2- year recurrence-free survival （RFS） of the treatment group and the control group were 51.3% vs. 61.5 %, 25.6% vs. 20.5%, there were no statistically significant differences between the two groups（P=0. 361 ,P=0. 591）. The 1- year and 2-year overall survival period of the treatment group and the control group were 64.1% vs. 69.2 %, 30.8% vs. 25.6 % ,respectively, there were also no sta- tistically significant differences between two groups（P= 0. 631 ,P= 0. 615）. The mainly adverse reactions of the two groups were myelosuppression,gastrointestinal reactions, hand-foot syndrome, mucositis, peripheral nerve toxicity, hepatic and renal function damage. The occurrence rate of hand-foot syndrome in the control group was significantly higher than that in the treatment group （P=0. 001）, the adverse reactions were improved after symptomatic treatment. Conclusion Oxaliplatin plus S-1 and oxaliplatin plus capecitabine are therapeutic equivalence and well tolerated in the patients with postoperative gastric cancer.
出处
《重庆医学》
CAS
CSCD
北大核心
2013年第26期3107-3109,共3页
Chongqing medicine
关键词
胃肿瘤
抗肿瘤联合化疗方案
奥沙利铂
gastric neoplasms
antineoplastic combined chemotherapy protocots
oxaliplatin
